J B Chemicals Pharmaceuticals Limited

J. B. Chemicals & Pharmaceuticals Limited (JBCPL) was established on December 18, 1976, in Mumbai, Maharashtra, India. The company specializes in the manufacturing and marketing of pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (APIs). Its diverse product portfolio spans various therapeutic areas, including cardiovascular, antimalarial, antiparasitic, and central nervous system (CNS) disorders.

As of March 2026, JBCPL reported a revenue of ₹3,333.32 crore and a net worth of ₹2,886.26 crore. The company employs approximately 5,984 professionals across its operations. JBCPL is listed on the Bombay Stock Exchange (BSE) under the ticker symbol 506943 and on the National Stock Exchange (NSE) under JBCHEPHARM. The company's Corporate Identification Number (CIN) is L24390MH1976PLC019380.

JBCPL operates multiple state-of-the-art manufacturing facilities across India, including locations in Thane, Belapur, Ankleshwar, Panoli, and Daman. These facilities are equipped to produce a wide range of pharmaceutical formulations, herbal remedies, and APIs, ensuring compliance with global quality standards. The company's manufacturing units are certified by prominent global regulators, reflecting its commitment to quality and compliance.

As of March 2026, the key leadership at JBCPL includes:

• Nikhil Ashokkumar Chopra: Chief Executive Officer (CEO) and Whole-Time Director.

• Sumit Bose: Non-Executive & Independent Director.

• Gaurav Trehan: Non-Executive Director.

• Richa Arora: Non-Executive Independent Director.

• Ashwani Kumar Puri: Non-Executive Independent Director.

• Prashant Kumar: Non-Executive Director.

• Akshay Tanna: Non-Executive & Non-Independent Director.

JBCPL has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained approvals for its pharmaceutical formulations from regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. These approvals facilitate the company's market access and distribution in these regions. JBCPL's commitment to quality and compliance is further demonstrated by its adherence to Good Manufacturing Practices (GMP) and other regulatory standards.

JBCPL has expanded its footprint in emerging markets, including Africa, Latin America, and Southeast Asia. The company's products are available in over 40 countries, reflecting its global reach and commitment to providing quality healthcare solutions. JBCPL's adherence to World Health Organization (WHO) prequalification standards has enabled it to access and supply medicines in these regions, ensuring the availability of essential pharmaceuticals to diverse populations.

JBCPL's geographic strategy involves diversification across various international markets, balancing its presence in both regulated and emerging markets. This approach mitigates concentration risk and leverages growth opportunities in different regions. The company's strategic direction focuses on expanding its product portfolio, enhancing manufacturing capabilities, and strengthening distribution networks to support its global operations. JBCPL's commitment to quality and compliance underpins its strategic initiatives, ensuring sustainable growth and market competitiveness.

JBCPL has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), enabling the company to market its pharmaceutical formulations in the United States. The company has received approvals for its Abbreviated New Drug Applications (ANDAs) and has filed Drug Master Files (DMFs) for its active pharmaceutical ingredients (APIs). JBCPL's facilities have undergone FDA inspections, and the company maintains a history of compliance with FDA regulations, reflecting its commitment to quality and regulatory adherence.

JBCPL's manufacturing facilities are certified by the World Health Organization (WHO) and the European Union (EU) Good Manufacturing Practices (GMP) standards. These certifications affirm the company's adherence to international quality standards, ensuring the safety and efficacy of its pharmaceutical products. The company's commitment to maintaining WHO and EU GMP certifications underscores its dedication to delivering high-quality medicines to global markets.

In India, JBCPL holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority. The company has obtained approvals from state drug controllers for its pharmaceutical formulations and has received export No Objection Certificates (NOCs) from the Directorate General of Foreign Trade (DGFT), facilitating its export activities. JBCPL's compliance with Indian regulatory requirements reflects its commitment to maintaining high standards of quality and safety in its operations.

As of March 2026, there have been no publicly reported Form 483 observations, warning letters, or import alerts issued by the U.S. FDA or other regulatory bodies against JBCPL. The company's adherence to regulatory standards and commitment to quality have contributed to its positive compliance history. JBCPL continues to monitor and address regulatory requirements to maintain its standing in global markets.

JBCPL operates in a competitive pharmaceutical industry, facing competition from both domestic and international companies. Its product portfolio, including formulations such as nifedipine, atenolol, mebendazole, lorazepam, and nicotine, positions it in therapeutic categories like cardiovascular, antimalarial, antiparasitic, and CNS disorders. The company's market share in these categories reflects its competitive standing. JBCPL's focus on quality, regulatory compliance, and strategic market expansion contributes to its competitive edge in the industry.

JBCPL's key differentiators include its diverse product portfolio across multiple therapeutic areas, strong presence in both regulated and emerging markets, and commitment to quality and regulatory compliance. The company's state-of-the-art manufacturing facilities, certified by global regulators, ensure the production of high-quality pharmaceutical formulations. JBCPL's strategic focus on expanding its product offerings and enhancing its global footprint positions it as a competitive player in the pharmaceutical industry.

JBCPL's current strategic direction emphasizes the expansion of its generics portfolio, development of specialty products, and exploration of biosimilars and contract development and manufacturing organization (CDMO) services. The company's focus on chronic-therapy portfolios, CDMO capacity, and wellness offerings across emerging markets aligns with its growth objectives. JBCPL's commitment to innovation, quality, and regulatory compliance supports its strategic initiatives and future outlook.

JBCPL has a strong track record in the pharmaceutical industry, with consistent export volumes and a diverse product portfolio. The company's adherence to international quality standards and regulatory requirements enhances its reliability as a supplier. JBCPL's commitment to ethical practices, patient-centric approaches, and on-time delivery further underscores its dependability in the global pharmaceutical market.

Importers should verify the following certifications when considering JBCPL as a supplier:

• FDA Registration: Confirm the company's registration status with the U.S. FDA to ensure compliance with U.S. regulations.

• WHO-GMP Certification: Verify the company's adherence to World Health Organization Good Manufacturing Practices.

• EU GMP Certification